TrialInternational journal of clinical oncology2022

Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.

Satoshi Tamada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.